Does Blue Cross Blue Shield of Michigan Cover Trulicity?

How BCBSM Formulary Coverage Works for Trulicity

Blue Cross Blue Shield of Michigan maintains multiple formulary lists depending on plan type: commercial HMO, PPO, Medicare Advantage, and self-funded employer plans. Trulicity (dulaglutide) appears on most of these formularies as a covered GLP-1 receptor agonist for type 2 diabetes. The FDA approved dulaglutide in 2014 for glycemic control in adults with type 2 diabetes, and it has since become one of the most widely prescribed once-weekly injectables in its class.

Formulary Tier Placement

BCBSM typically places Trulicity on Tier 2 (preferred brand) or Tier 3 (non-preferred brand), depending on the specific plan design. Tier placement directly affects your copay. Preferred brand placement generally means lower out-of-pocket costs compared to non-preferred status.

How Plan Type Affects Your Coverage

Commercial PPO and HMO plans through BCBSM tend to offer the broadest GLP-1 coverage. Self-funded employer plans may adopt different formulary structures entirely, since the employer (not BCBSM) makes final coverage decisions. Medicare Advantage plans offered by BCBSM follow CMS guidelines requiring coverage of FDA-approved diabetes medications on at least one formulary tier.

Checking Your Specific Plan

The most reliable way to confirm your coverage is to log into your BCBSM member portal or call the number on your insurance card. Formulary placement can shift during annual plan renewals, so even if Trulicity was covered last year, the tier or prior authorization requirements may have changed.

Prior Authorization and Step Therapy Requirements

Most BCBSM plans require prior authorization before dispensing Trulicity. This means your prescriber must submit clinical documentation proving medical necessity. The American Diabetes Association Standards of Care recommend GLP-1 receptor agonists as second-line therapy after metformin, and BCBSM's step therapy protocols generally mirror this recommendation.

What BCBSM Typically Requires for Approval

Your provider will usually need to document three things: a confirmed hemoglobin A1c level above target (generally 7.0% or higher per ADA guidelines), a trial of metformin lasting at least 90 days (or documented intolerance/contraindication), and a statement that the requested GLP-1 is appropriate for the patient's clinical profile.

How Long Approval Takes

Standard prior authorization decisions from BCBSM are typically completed within 72 hours for non-urgent requests. Urgent requests can be processed within 24 hours. If denied, your prescriber can file a peer-to-peer appeal. Denial rates vary, but documented metformin failure and an A1c above 8.0% significantly increase approval likelihood.

When Step Therapy May Be Waived

BCBSM may waive step therapy if you have a documented contraindication to metformin, such as an eGFR below 30 mL/min/1.73 m², a history of lactic acidosis, or severe gastrointestinal intolerance. Patients with established atherosclerotic cardiovascular disease (ASCVD) may also qualify for expedited approval, given that the REWIND trial (N=9,901) demonstrated a 12% reduction in major adverse cardiovascular events (MACE) with dulaglutide.

What Trulicity Costs with BCBSM Insurance

Without insurance, Trulicity's list price runs approximately $1,000 to $1,100 for a 28-day supply of four pens. With BCBSM coverage, your actual out-of-pocket cost depends on tier placement, your plan's cost-sharing structure, and whether you've met your deductible.

Commercial Plan Cost Estimates

On a preferred brand tier, expect copays between $25 and $75 per month. Non-preferred brand placement pushes copays higher, typically $75 to $150. Some high-deductible health plans (HDHPs) require you to pay full price until the deductible is met, though preventive drug lists may apply to diabetes medications in certain plan designs.

Medicare Advantage and Part D Costs

BCBSM Medicare Advantage plans cover Trulicity under Part D prescription drug benefits. Specialty tier copays on Medicare Part D typically range from 25% to 33% coinsurance after the deductible phase. The Medicare Part D coverage gap (formerly the "donut hole") was effectively closed by the Inflation Reduction Act, capping annual out-of-pocket drug spending at $2,000 starting in 2025.

Manufacturer Savings Programs

Eli Lilly offers a Trulicity Savings Card for commercially insured patients, potentially reducing copays to as low as $25 per fill. This card does not apply to government-funded insurance (Medicare, Medicaid, Tricare). Eligible patients can use the card for up to 24 months. Your pharmacist can apply it at the point of sale alongside your BCBSM benefits.

Clinical Evidence Supporting Trulicity Coverage

Insurance coverage decisions for GLP-1 receptor agonists are informed by clinical trial data. Trulicity has one of the most extensive evidence bases among GLP-1 medications, with multiple Phase III trials supporting its efficacy across different patient populations.

The AWARD Trial Program

The AWARD (Assessment of Weekly AdministRation of LY2189265 in Diabetes) trial program included nine major studies. In AWARD-1 (N=978), dulaglutide 1.5 mg reduced A1c by 1.51% at 52 weeks compared to 0.99% with exenatide twice daily. AWARD-5 (N=1,098) demonstrated A1c reductions of 1.10% with dulaglutide 1.5 mg versus 0.87% with sitagliptin at 52 weeks.

Cardiovascular Outcomes Data

The REWIND trial was a landmark cardiovascular outcomes study enrolling 9,901 patients with type 2 diabetes, 69% of whom did not have established cardiovascular disease at baseline. Over a median follow-up of 5.4 years, dulaglutide reduced the composite MACE endpoint by 12% (HR 0.88, 95% CI 0.79-0.99). This trial was notable for its inclusion of a broader population than most GLP-1 cardiovascular outcomes studies.

Weight Loss Outcomes

While Trulicity is not FDA-approved for weight management, clinical trials consistently showed weight reduction. In AWARD-11 (N=1,842), the higher 4.5 mg dose produced mean weight loss of 4.6 kg (approximately 10 pounds) at 36 weeks. The ADA 2024 Standards of Care recognize weight reduction as a secondary benefit of GLP-1 receptor agonists in type 2 diabetes management.

Trulicity Dosing and How It Affects Coverage

Trulicity is available in four FDA-approved doses: 0.75 mg, 1.5 mg, 3.0 mg, and 4.5 mg, all administered once weekly via a single-use prefilled pen. BCBSM quantity limits align with standard prescribing: four pens per 28 days for the 0.75 mg and 1.5 mg strengths, or two pens per 28 days for the 3.0 mg and 4.5 mg strengths. Per the prescribing information, the recommended starting dose is 0.75 mg weekly.

Dose Escalation and Insurance Approvals

Starting at 0.75 mg and escalating to 1.5 mg after four weeks is standard protocol. The 3.0 mg and 4.5 mg doses, added via supplemental FDA approval in 2020, may require separate prior authorization from BCBSM. Your provider may need to demonstrate inadequate glycemic control on the lower doses before the higher doses are approved.

Injection Technique and Adherence

Once-weekly dosing is a significant adherence advantage. The Trulicity pen does not require manual needle attachment. Patients press the pen against the abdomen, thigh, or upper arm and click. This device design contributed to higher patient satisfaction scores compared to other injectable GLP-1s in the PREFER study (N=345).

Alternatives If BCBSM Denies Trulicity Coverage

If your BCBSM plan denies Trulicity coverage or places it on a high-cost tier, several alternatives exist within the GLP-1 receptor agonist class. Formulary preference varies by plan year.

Other GLP-1 Options on BCBSM Formularies

Ozempic (semaglutide) may be on a preferred tier for some BCBSM plans. In the SUSTAIN-7 trial (N=1,201), semaglutide 1.0 mg produced greater A1c reduction (1.8%) than dulaglutide 1.5 mg (1.4%) at 40 weeks. Rybelsus (oral semaglutide) offers a non-injectable alternative. Mounjaro (tirzepatide), a dual GIP/GLP-1 agonist, showed superior A1c and weight reduction in the SURPASS-2 trial (N=1,879) compared to semaglutide 1.0 mg.

Non-GLP-1 Alternatives

If GLP-1 coverage is restricted entirely, SGLT2 inhibitors like empagliflozin and dapagliflozin offer cardiovascular and renal benefits alongside glycemic control. The EMPA-REG OUTCOME trial (N=7,020) showed a 38% reduction in cardiovascular death with empagliflozin. DPP-4 inhibitors (sitagliptin, linagliptin) are generally available on lower formulary tiers with smaller copays, though they produce more modest A1c reductions of approximately 0.5% to 0.8%.

The Appeals Process

If Trulicity is denied, your prescriber can submit an appeal with supporting clinical documentation. Include your A1c history, a list of prior diabetes medications tried, and relevant comorbidities (ASCVD, CKD, obesity). Reference the ADA consensus report on GLP-1 use to strengthen the case. External review by an independent organization is available if internal appeals are exhausted, per Michigan insurance regulations.

Who Should Consider Trulicity Through BCBSM

Trulicity is FDA-approved specifically for adults with type 2 diabetes to improve glycemic control alongside diet and exercise. Certain patient profiles may receive faster or more favorable coverage decisions from BCBSM.

Strongest Coverage Cases

Patients with type 2 diabetes and established ASCVD have the strongest clinical and insurance justification for Trulicity, based on the REWIND cardiovascular benefit data. Those with A1c values above 8.0% despite metformin at maximally tolerated doses also present a straightforward prior authorization case.

Patients Who May Face Coverage Barriers

BCBSM plans do not cover Trulicity for weight loss alone in patients without type 2 diabetes. Patients with a history of medullary thyroid carcinoma or MEN2 syndrome have a labeled contraindication. Those with a personal or family history of pancreatitis may face additional scrutiny, although the FDA label notes that post-marketing reports of acute pancreatitis remain rare.

Working with Your Provider

Ask your prescriber to check the BCBSM formulary before writing the prescription. If Trulicity is non-preferred, requesting a therapeutic alternative on a preferred tier can save significant out-of-pocket cost. A pharmacy benefits specialist at your provider's office can often handle the prior authorization process within one to two business days.

Important Safety Information

Common side effects of dulaglutide include nausea (reported in 12.4% of patients on the 1.5 mg dose in clinical trials), diarrhea (8.9%), vomiting (6.9%), and abdominal pain (6.5%), per FDA prescribing information. Most gastrointestinal side effects diminish within the first four to eight weeks. The FDA black box warning notes that dulaglutide caused dose-dependent thyroid C-cell tumors in rodents; relevance to humans is unknown, but it is contraindicated in patients with MTC or MEN2.

Patients should report persistent severe abdominal pain to their provider to rule out pancreatitis. Hypoglycemia risk is low with dulaglutide monotherapy but increases when combined with insulin or sulfonylureas. The Endocrine Society clinical practice guideline recommends monitoring renal function in patients reporting severe GI side effects, as dehydration from nausea and vomiting can affect kidney function.